GSK’s Victory In Zofran Product Liability Cases Shows Power Of Communications With US FDA
Executive Summary
In granting GlaxoSmithKline’s motion for summary judgment in multidistrict litigation, judge notes FDA rejected requests to change warning label about use in pregnant women multiple times and would not have approved warnings sought by plaintiffs.